My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 151

    1.

    Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine.

    Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R; ATLANTUS Study Group.

    Diabetes Care. 2005 Jun;28(6):1282-8.PMID: 15920040 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial.

    Davies M, Lavalle-González F, Storms F, Gomis R; AT.LANTUS Study Group.

    Diabetes Obes Metab. 2008 May;10(5):387-99. Epub 2008 Mar 18.PMID: 18355327 [PubMed - indexed for MEDLINE]Related articles

    3.

    Dosing of insulin glargine in the treatment of type 2 diabetes.

    Barnett A.

    Clin Ther. 2007 Jun;29(6):987-99. Review.PMID: 17692716 [PubMed - indexed for MEDLINE]Related articles

    4.

    Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.

    Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME.

    Clin Ther. 2007 Nov;29(11):2333-48.PMID: 18158075 [PubMed - indexed for MEDLINE]Related articles

    5.

    Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial.

    Kennedy L, Herman WH, Strange P, Harris A; GOAL AIC Team.

    Diabetes Care. 2006 Jan;29(1):1-8.PMID: 16373887 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.

    Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group.

    Ann Intern Med. 2005 Oct 18;143(8):559-69.PMID: 16230722 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies.

    Davies M, Sinnassamy P, Storms F, Gomis R; AT.LANTUS Study Group.

    Diabetes Res Clin Pract. 2008 Feb;79(2):368-75. Epub 2007 Nov 5.PMID: 17980928 [PubMed - indexed for MEDLINE]Related articles

    8.

    Improving metabolic control in sub-optimally controlled subjects with Type 1 diabetes: comparison of two treatment algorithms using insulin glargine.

    Gomis R, Storms F, Conget I, Sinnassamy P, Davies M; AT.LANTUS Study Group.

    Diabetes Res Clin Pract. 2007 Jul;77(1):84-91. Epub 2006 Nov 9.PMID: 17097185 [PubMed - indexed for MEDLINE]Related articles

    9.

    Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.

    Esposito K, Ciotola M, Maiorino MI, Gualdiero R, Schisano B, Ceriello A, Beneduce F, Feola G, Giugliano D.

    Ann Intern Med. 2008 Oct 21;149(8):531-9.PMID: 18936501 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.

    Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH; Lispro Mixture-Glargine Study Group.

    Clin Ther. 2004 Dec;26(12):2034-44. Erratum in: Clin Ther. 2005 Jul;27(7):1112. PMID: 15823767 [PubMed - indexed for MEDLINE]Related articles

    11.

    Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK.

    Davies M, Evans R, Storms F, Gomis R, Khunti K.

    Diabetes Obes Metab. 2007 Sep;9(5):706-13.PMID: 17697063 [PubMed - indexed for MEDLINE]Related articles

    12.

    The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

    Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators.

    Diabetes Care. 2003 Nov;26(11):3080-6.PMID: 14578243 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

    Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles

    14.

    Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.

    Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H.

    Diabetes Care. 2005 Feb;28(2):254-9.PMID: 15677775 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes.

    Hamann A, Matthaei S, Rosak C, Silvestre L; HOE901/4007 Study Group.

    Diabetes Care. 2003 Jun;26(6):1738-44.PMID: 12766103 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.

    Janka HU, Plewe G, Busch K.

    J Am Geriatr Soc. 2007 Feb;55(2):182-8.PMID: 17302653 [PubMed - indexed for MEDLINE]Related articles

    17.

    Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.

    Riddle M, Frias J, Zhang B, Maier H, Brown C, Lutz K, Kolterman O.

    Diabetes Care. 2007 Nov;30(11):2794-9. Epub 2007 Aug 13.PMID: 17698615 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study.

    Raz I, Stranks S, Filipczak R, Joshi P, Lertoft B, Rastam J, Chow CC, Shaban J.

    Clin Ther. 2005 Sep;27(9):1432-43.PMID: 16291416 [PubMed - indexed for MEDLINE]Related articles

    19.

    Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

    Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

    Clin Ther. 2008 Aug;30(8):1448-60. Erratum in: Clin Ther. 2008 Oct;30(10):1937. PMID: 18803987 [PubMed - indexed for MEDLINE]Related articles

    20.

    Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

    Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

    Diabetes Care. 2006 Mar;29(3):554-9.PMID: 16505505 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity